Total
0
Shares
Cynata Therapeutics (ASX:CYP) - CEO, Dr Ross Macdonald
CEO, Dr Ross Macdonald
Source: Finance News Network
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Cynata Therapeutics (CYP) has received ethics committee approval to expand the recruitment criteria of its MEND clinical trial
  • The trial was originally designed to test the company’s Cymerus mesenchymal stem cells in people with COVID-related respiratory failure
  • The trial will now expand to include patients with respiratory failure arising from other causes besides COVID-19 
  • This change will increase the pool of eligible patients, thereby accelerating recruitment and completion of the trial
  • Cynata Therapeutics is down 3.17 per cent and trading at 61 cents per share

Cynata Therapeutics (CYP) has received ethics committee approval to expand the recruitment criteria of its MEND clinical trial.

The company’s mesenchymal COVID-19 (MEND) trial is an open-label, randomised controlled clinical trial, which is currently active. The trial was originally designed to test the efficacy of Cynata’s mesenchymal stem cells (MSCs) in patients suffering from respiratory failure caused by COVID-19. 

However, COVID-19 is not the only disease capable of resulting in respiratory failure, or acute respiratory distress syndrome (ARDS). Additionally, Australia’s successful suppression of the COVID-19 pandemic means that there are not many people in the country who would be eligible under the trial’s current parameters.

As such, the trial will now expand to include patients in intensive care, who have been admitted with respiratory failure arising from other causes besides COVID-19. With COVID-19 no longer a requirement of eligibility, Cynata’s trial will be able to test its MSC’s in people with respiratory distress caused by diseases such as influenza.

The company is now looking to enrol 24 adult patients, who have been admitted to intensive care with respiratory distress or compromised lung function in select Australian hospitals.

Cynata’s Chief Operating Officer, Dr Kilian Kelly, commented that the clinical trial expansion will substantially increase the catchment of patients, thereby accelerating recruitment for and completion of the MEND trial.

“We have developed a solid pre-clinical data set in relevant diseases models of the severe respiratory distress and associated complications suffered by many patients affected by respiratory viruses such as SARS-CoV-2 (the virus that causes COVID-19) and influenza,” he said.

“This expansion will increase the number of patients eligible for recruitment into this trial, which is designed to investigate the potential benefits of our MSCs in treating these severely ill patients,” he added.

Cynata Therapeutics is down 3.17 per cent, trading at 61 cents per share at 2:42 pm AEDT.

CYP by the numbers
More From The Market Herald
Advanced Human Imaging, AHI- CEO and Co-Founder Vlado Bosanac

" Advanced Human Imaging (ASX:AHI) appoints Edward F. Greissing Jr. to board

Advanced Human Imaging (AHI) has appointed Edward F. Greissing Jr. to board effective from November 30, 2021.
Rhythm Biosciences (ASX:RHY) - CEO, Glenn Gilbert

" Rhythm Biosciences (ASX:RHY) achieves CE Mark for ColoSTAT

Cancer diagnostic technology company Rhythm Biosciences (RHY) has achieved CE Mark certification for ColoSTAT.
EMVision Medical Devices (ASX:EMV) - CEO, Ron Weinberger

" EMVision Medical Devices (ASX:EMV) reports more strong results

Medical device maker EMVision (EMV) is spiking on the ASX today after releasing further results from a pilot clinical trial of its brain
ECS Botanics (ASX:ECS) - Managing Director and Founder, Alex Keach

" ECS Botanics’ (ASX:ECS) subsidiary buds $4.9m supply agreement

ECS Botanics’ (ECS) subsidiary has secured a $4.9 million agreement to supply resin to Australian cannabis company, Cannvalate.